Could a genetic marker guide future cancer therapies in taiwan?

NCT ID NCT06665776

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This study is measuring how often a specific genetic marker (HLA-A*02:01) and a cancer-related protein (NY-ESO-1) appear in Taiwanese patients with solid tumors like head and neck, liver, lung, breast, and esophageal cancers. By understanding these frequencies, researchers hope to identify which patients might benefit from future targeted immunotherapies. The study involves collecting blood and tumor tissue samples from about 485 participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If certain markers are common, this could help design targeted immunotherapies for Taiwanese cancer patients.
What could go wrong
This is an observational study only—it does not test any treatment. The findings may not lead to new therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Chang Gung Memorial Hospital, Chiayi Branch

    Chiayi City, Taiwan, Taiwan

  • National Cheng Kung University Hospital

    Tainan, Taiwan, 704, Taiwan

  • National Taiwan University Hospital

    Taipei, Taiwan, Taiwan

  • Taichung Veterans General Hospital

    Taichung, Taiwan, 407219, Taiwan

  • Taipei Medical University Hospital

    Taipei, Taiwan, Taiwan

  • Taipei Veterans General Hospital

    Taipei, Taiwan, 11217, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.